Eosinophilic Esophagitis

Immunology·MeSH: Eosinophilic Esophagitis

10 drugs in development·6 companies·8 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
Barzolvolimab (CDX-0159)	Celldex Therapeutics, Inc. (CLDX)
Vonoprazan	Phathom Pharmaceuticals, Inc. (PHAT)
vonoprazan (VOQUEZNA)	Phathom Pharmaceuticals, Inc. (PHAT)
vonoprazan (VOQUEZNA) - as-needed regimen	Phathom Pharmaceuticals, Inc. (PHAT)
vonoprazan (VOQUEZNA) - EoE	Phathom Pharmaceuticals, Inc. (PHAT)

Phase 2(3)

Drug	Company
barzolvolimab	Celldex Therapeutics, Inc. (CLDX)
etrasimod	ARENA PHARMACEUTICALS INC (ARNA)
zumilokibart	Apogee Therapeutics, Inc. (APGE)

Phase 1(1)

Drug	Company
ANB033	ANAPTYSBIO, INC (ANAB)

Phase 1/Phase 2(1)

Drug	Company
ep-104gi	EUPRAXIA PHARMACEUTICALS INC. (EPRX)

BioSniper tracks 10 drugs in development for Eosinophilic Esophagitis across 6 companies.

There are 8 clinical trials targeting Eosinophilic Esophagitis tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.